In an attempt to expand its respiratory portfolio, Merck & Co. has agreed to acquire Verona Pharma for a total equity value of approximately US$10 B. Through this strategic takeover, Merck picks up Verona’s Ohtuvayre (ensifentrine), a treatment for chronic obstructive pulmonary disease (COPD) that secured US approval in 2024. The deal provides Merck with a significant opportunity to strengthen and expand its focus on its respiratory disease portfolio as it braces for the looming patent expiration on its blockbuster cancer drug, Keytruda.